Atopic Dermatitis (AD)

HKB's NHP Atopic Dermatitis Models provide pharmaceutical researchers with scientifically rigorous platforms for developing AD therapeutics. Our non-human primate models successfully recapitulate the chronic inflammatory characteristics of atopic dermatitis, including skin barrier dysfunction, IgE elevation, and Th2-skewed immune responses. Each model features comprehensive validation with clinical scoring systems, transepidermal water loss measurements, and histopathological assessments. The translational relevance of NHP models ensures high concordance with human clinical responses, enabling more confident go/no-go decisions.